Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.40 |
| ▸ | CA12 | O43570 | 12/20 | 0.40 |
| ▸ | CA9 | Q16790 | 11/20 | 0.40 |
| ▸ | CA1 | P00915 | 11/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479802 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1OGA | |
| SCHEMBL1266094 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL21510391 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL8329413 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL7151917 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL8358880 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL7154470 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL7152812 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL7151553 | 0.79 | TSHR (0.44) | CA2CA12CA9CA1OGA | |
| SCHEMBL10831614 | 0.74 | CA9 (0.36) | CA2CA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3231804-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3231804-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2268647-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9005578-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | FLUOROPHARMA, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2015-04-09 | — | — | US | disclosed |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | FLUOROPHARMA, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8450466-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPTIAL CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2011-03-10 | — | — | US | disclosed |
| EP-2268647-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117728-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| US-4877220-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, PSEN1, PSEN2 | CA2 180/4885CA12 53/4885CA9 146/4885 |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | APP, PSEN1, PSEN2 | CA2 180/4885CA12 53/4885CA9 146/4885 |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | CA2 180/4885CA12 53/4885CA9 146/4885 |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | CA2 180/4885CA12 53/4885CA9 146/4885 |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | CA2 180/4885CA12 53/4885CA9 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.